AF
CPRX

Amalgamated Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Amalgamated Financial’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$97K Buy
+11,690
New +$82.6K ﹤0.01% 2156

Other funds holding CPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Amalgamated Financial's CPRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2022: 11,690 shares worth $97K. The stake represents ﹤0.01% of the portfolio and ranks #2156 among its holdings.

187 funds tracked by Wall St. Rank hold CPRX as of Q1 2022.

  • Amalgamated Financial held 11,690 shares of Catalyst Pharmaceutical worth $97K as of Q1 2022.
  • Catalyst Pharmaceutical was a new Amalgamated Financial position in Q1 2022.
  • Catalyst Pharmaceutical made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2156 holding.
  • 187 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.